Clinical Trial

JAK Inhibitors for Solid Malignant Tumor Patients With Immune Checkpoint Inhibitors-related Dermatitis: A Open-lable, Single Arm, Phase IIa Trial

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated October 28, 2025 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.
Summary
Currently, the principal strategy for immune checkpoint inhibitors (ICI)-related dermatitis include systemic use of corticosteroids, which can impair the efficacy of preceding ICIs treatment. Janus kinase inhibitors (JAKi) could be the optimal option for ICI-related dermatitis, which can not only provide rapid relief for ICI-related dermatitis but also potentially enhance the anti-tumor efficacy of ICIs. This is an open-lable, single arm, phase II trial, aims to evaluate efficacy and safety of JAK inhibitors for solid malignant tumor patients with ICI-related dermatitis.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-11-28; most recent amendment 2025-10-26.
Status change: Not Yet Recruiting → Recruiting 2025-09-05
Trial Details
NCT Number NCT06715982
Lead Sponsor Shixiu Wu
Conditions Immune Checkpoint Inhibitors (ICI)-Related Dermatitis
Enrollment 35 participants
Start Date 2024-12-31
Primary Completion 2025-12 (estimated)
Study Completion 2025-12 (estimated)
Updated on ClinicalTrials.gov 2025-10-28